Car T-Cell Therapy

Researchers in China identified an increased risk for symptomatic venous thromboembolism in patients hospitalized with COVID-19. It was the top story in hematology/oncology last week.

Kite Pharma submitted a supplemental biologics license application to the FDA for brexucabtagene autoleucel to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to the agent’s manufacturer.

Steroids are commonly used to mitigate severe treatment-related adverse events associated with chimeric antigen receptor T-cell therapy.

The FDA approved idecabtagene vicleucel, a chimeric antigen receptor T-cell therapy, for treatment of adults with relapsed or refractory multiple myeloma.

Chimeric antigen receptor T-cell therapy weakens the immune system, leaving the recipient vulnerable to infection. An in-depth look at the infection risk associated with this treatment was the top story in hematology/oncology last week.

Although chimeric antigen receptor T-cell therapies are being administered more frequently, they are still available only at a limited number of specialized centers.

Chimeric antigen receptor T-cell therapy employs a patient’s immune system to fight cancer and thereby weakens it, leaving the recipient vulnerable to infection.

Colorectal Cancer Awareness Month is observed in March.

The Parker Institute for Cancer Immunotherapy awarded nearly $3 million worth of grants to six early career researchers.

Immune dysregulation resulting from high tumor burden appeared associated with poor chimeric antigen receptor T-cell expansion and resistance among patients with diffuse large B-cell lymphoma, according to study results published in Blood.